CME

Faculty: Kathleen N. Moore, MD

Faculty: Ritu Salani, MD

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

Host: Alex F. Herrera, MD

This online activity is designed to provide the healthcare team with the latest developments and critical insights into Hodgkin lymphoma treatment. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

This online education activity will clearly and accurately present recent clinical trial data evidencing superior outcomes for adults and children with cHL who are treated with ICIs, compared with established chemotherapy regimens and/or brentuximab vedotin, in both the R/R and frontline settings.

Faculty: Michael A. Levine, MD, ML, MACE

Faculty: Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR

In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and highlight key efficacy and safety findings, including reductions in hypercalciuria and the potential implications for long-term renal health. The faculty also examine the role of genetic testing in establishing an accurate diagnosis, guiding family screening, and preparing clinicians for emerging precision medicine approaches in ADH1.

Faculty: Neal Ready, MD, PhD

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

Faculty: Neal Ready, MD, PhD

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

Faculty: Ticiana Leal, MD

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

Faculty: Ticiana Leal, MD

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

Faculty: Sara A. Hurvitz, MD, FACP

Faculty: Tiffany Traina, MD, FASCO

The role of antibody-drug conjugate (ADC) therapy has been well established in metastatic breast cancer. Recent phase 3 data have provided evidence for expanded indications for early breast cancer and triple-negative breast cancer (TNBC), leading to updates in current treatment guidelines. In this case-based activity, Drs. Tiffany Traina and Sara Hurvitz explore the supporting data for use of ADCs in the neoadjuvant, post-neoadjuvant, and metastatic TBNC settings.

Faculty: Maria Fleseriu, MD, FACE

Faculty: Beverly MK Biller, MD, FACP

Faculty: Mark Gurnell, MD

This program is a replay of the live symposium held at ENDO 2026. This program reviews challenges in diagnosis and management of acromegaly, with an emphasis on earlier recognition and informed clinical decision-making. Faculty discuss heterogeneity of disease presentation and key triggers that should prompt biochemical testing. Guideline-informed strategies for treatment selection, sequencing, and optimization are reviewed for patients with partial disease control, persistent symptoms, or comorbidities. The activity also examines disease burden, therapeutic inertia, and emerging treatment options, including oral therapies, with a focus on individualized care for patients with acromegaly in endocrine practice.

Faculty: Christophe Le Tourneau, MD, PhD

Faculty: Marc Oliva, MD, PhD

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.